Author:
Cavenagh J,Oakervee H,Baetiong-Caguioa P,Davies F,Gharibo M,Rabin N,Kurman M,Novak B,Shiraishi N,Nakashima D,Akinaga S,Yong K
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia 22 (22): 231–239.
2. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 15 (16): 5250–5257.
3. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (2009) US Department of Health and Human Services. Available at:
http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf
(accessed 25 August 2015).
4. Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20 (9): 1467–1473.
5. Ishii T, Seiki T, Nakashima T, Juliger S, Maharaj L, Soga S, Akinaga S, Cavenagh J, Joel S, Shiotsu Y (2012) Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J 2 (4): e68.
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献